Insight Molecular Diagnostics Inc.IMDXEarnings & Financial Report
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Revenue
$260.0K
Gross Profit
$139.0K
Operating Profit
$-11.0M
Net Profit
$-10.9M
Gross Margin
53.5%
Operating Margin
-4249.2%
Net Margin
-4174.6%
YoY Growth
126.1%
EPS
$-0.34
Insight Molecular Diagnostics Inc. Q3 FY2025 Financial Summary
Insight Molecular Diagnostics Inc. reported revenue of $260.0K (up 126.1% YoY) for Q3 FY2025, with a net profit of $-10.9M (up 19.6% YoY) (-4174.6% margin). Cost of goods sold was $121.0K, operating expenses totaled $11.2M.
Key Financial Metrics
| Total Revenue | $260.0K |
|---|---|
| Net Profit | $-10.9M |
| Gross Margin | 53.5% |
| Operating Margin | -4249.2% |
| Report Period | Q3 FY2025 |
Insight Molecular Diagnostics Inc. Annual Revenue by Year
Insight Molecular Diagnostics Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $4.1M |
| 2024 | $1.9M |
| 2023 | $1.5M |
| 2022 | $958.0K |
Insight Molecular Diagnostics Inc. Quarterly Revenue & Net Profit History
Insight Molecular Diagnostics Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.1M | -23.4% | $-23.0M | -2015.4% |
| Q3 FY2025 | $260.0K | +126.1% | $-10.9M | -4174.6% |
| Q2 FY2025 | $518.0K | +398.1% | $-9.7M | -1880.7% |
| Q1 FY2025 | $2.1M | +1114.8% | $-6.7M | -312.0% |
| Q4 FY2024 | $1.5M | +373.2% | $-33.5M | -2255.1% |
| Q3 FY2024 | $115.0K | -73.2% | $-13.5M | -11733.0% |
| Q2 FY2024 | $104.0K | -77.5% | $-4.5M | -4355.8% |
| Q1 FY2024 | $176.0K | -40.7% | $-9.1M | -5186.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $176000 | $104000 | $115000 | $1.5M | $2.1M | $518000 | $260000 | $1.1M |
| YoY Growth | -40.7% | -77.5% | -73.2% | 373.2% | 1114.8% | 398.1% | 126.1% | -23.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $71.0M | $74.7M | $70.2M | $35.1M | $60.4M | $50.5M | $43.9M | $25.8M |
| Liabilities | $54.1M | $52.0M | $60.5M | $47.4M | $50.1M | $49.4M | $53.1M | $57.2M |
| Equity | $11.6M | $22.7M | $9.7M | $-12.3M | $10.2M | $1.1M | $-9.2M | $-31.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.8M | $-6.0M | $-5.5M | $-5.4M | $-5.9M | $-6.3M | $-4.5M | $-5.5M |